{"id":"https://openalex.org/W7127574841","doi":"https://doi.org/10.1158/1078-0432.31248962","title":"Supplementary Figure S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial","display_name":"Supplementary Figure S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial","publication_year":2026,"publication_date":"2026-02-04","ids":{"openalex":"https://openalex.org/W7127574841","doi":"https://doi.org/10.1158/1078-0432.31248962"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.31248962","doi":"https://doi.org/10.1158/1078-0432.31248962","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31248962","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.31248962","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053983312","display_name":"Mafalda Oliveira","orcid":"https://orcid.org/0000-0001-9152-8799","observed_orcids":["https://orcid.org/0000-0001-9152-8799"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mafalda Oliveira","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9152-8799","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125076476","display_name":"Eva Ciruelos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eva Ciruelos","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2796-1042","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028946644","display_name":"Guillermo Javierre Villacampa","orcid":"https://orcid.org/0000-0003-4868-6585","observed_orcids":["https://orcid.org/0000-0003-4868-6585"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guillermo Villacampa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4868-6585","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085797367","display_name":"Serafin M. Morales","orcid":"https://orcid.org/0000-0001-7445-4193","observed_orcids":["https://orcid.org/0000-0001-7445-4193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Seraf\u00edn Morales","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7445-4193","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053044048","display_name":"Javier Salvador Bofill","orcid":"https://orcid.org/0000-0003-3043-4398","observed_orcids":["https://orcid.org/0000-0003-3043-4398"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Javier Salvador Bofill","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3043-4398","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088121773","display_name":"Vanesa Quiroga","orcid":"https://orcid.org/0000-0002-7852-474X","observed_orcids":["https://orcid.org/0000-0002-7852-474X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vanesa Quiroga","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7852-474X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112950203","display_name":"Joaqu\u00edn Gavil\u00e1","orcid":"https://orcid.org/0000-0002-6768-3833","observed_orcids":["https://orcid.org/0000-0002-6768-3833"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joaqu\u00edn Gavil\u00e1","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6768-3833","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057864168","display_name":"Alexandra Cortegoso","orcid":"https://orcid.org/0000-0003-4098-9266","observed_orcids":["https://orcid.org/0000-0003-4098-9266"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexandra Cortegoso","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4098-9266","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109380786","display_name":"Estela Vega","orcid":"https://orcid.org/0009-0005-5652-6460","observed_orcids":["https://orcid.org/0009-0005-5652-6460"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Estela Vega","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-5652-6460","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069061103","display_name":"Fernando Henao","orcid":"https://orcid.org/0000-0003-3819-9572","observed_orcids":["https://orcid.org/0000-0003-3819-9572"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fernando Henao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3819-9572","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006460186","display_name":"S\u00f2nia Servitja","orcid":"https://orcid.org/0000-0001-6988-4519","observed_orcids":["https://orcid.org/0000-0001-6988-4519","https://orcid.org/0009-0007-0758-7202"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sonia Servitja","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6988-4519","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008566812","display_name":"Pablo Tolosa","orcid":"https://orcid.org/0000-0002-3747-4766","observed_orcids":["https://orcid.org/0000-0002-3747-4766"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pablo Tolosa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3747-4766","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096170099","display_name":"Samyukta Chillara","orcid":"https://orcid.org/0000-0002-6072-5455","observed_orcids":["https://orcid.org/0000-0002-6072-5455"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Samyukta Chillara","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6072-5455","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108306687","display_name":"Milana A. Bergamino","orcid":"https://orcid.org/0000-0002-1091-2711","observed_orcids":["https://orcid.org/0000-0002-1091-2711"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Milana Bergamino","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1091-2711","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075332457","display_name":"Fernando Salvador","orcid":"https://orcid.org/0000-0002-5442-1754","observed_orcids":["https://orcid.org/0000-0002-5442-1754"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fernando Salvador","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5442-1754","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004368493","display_name":"Mariana Paes Dias","orcid":"https://orcid.org/0000-0002-5757-4211","observed_orcids":["https://orcid.org/0000-0002-5757-4211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mariana Paes Dias","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5757-4211","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032305758","display_name":"Juan Manuel Ferrero-Cafiero","orcid":"https://orcid.org/0000-0001-8796-8812","observed_orcids":["https://orcid.org/0000-0001-8796-8812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Juan M. Ferrero-Cafiero","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8796-8812","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025842545","display_name":"Xavier Gonz\u00e1lez","orcid":"https://orcid.org/0000-0002-5797-7037","observed_orcids":["https://orcid.org/0000-0002-5797-7037"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xavier Gonzalez Farre","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5797-7037","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5123616940","display_name":"Tom\u00e1s Pascual","orcid":"https://orcid.org/0000-0001-8431-3183","observed_orcids":["https://orcid.org/0000-0001-8431-3183"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tom\u00e1s Pascual","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8431-3183","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5082195410","display_name":"Cristina Saura","orcid":"https://orcid.org/0000-0001-8296-5065","observed_orcids":["https://orcid.org/0000-0001-8296-5065"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cristina Saura","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8296-5065","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.004800000227987766,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipatasertib","display_name":"ipatasertib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8149999976158142},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.906000018119812},{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.9639999866485596},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9750000238418579},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":1.0},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7319999933242798},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6990000009536743},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.6110000014305115}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.8777999877929688},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8586000204086304},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7534000277519226},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6970999836921692},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.641700029373169},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5791000127792358},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5286999940872192},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.511900007724762},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.48590001463890076},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.38989999890327454},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3781000077724457},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.36579999327659607},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34310001134872437},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.33239999413490295},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.32510000467300415},{"id":"https://openalex.org/C2780980858","wikidata":"https://www.wikidata.org/wiki/Q110022","display_name":"Dual (grammatical number)","level":2,"score":0.3084999918937683},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3041999936103821},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.30090001225471497},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.29679998755455017},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.27950000762939453},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.2766000032424927},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.25769999623298645},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.2515999972820282}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.31248962","doi":"https://doi.org/10.1158/1078-0432.31248962","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31248962","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:digital.csic.es:10261/435863","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10261/435863","pdf_url":null,"source":{"id":"https://openalex.org/S4306400616","display_name":"DIGITAL.CSIC (Spanish National Research Council (CSIC))","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I134820265","host_organization_name":"Consejo Superior de Investigaciones Cient\u00edficas","host_organization_lineage":["https://openalex.org/I134820265"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/dataset"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.31248962","doi":"https://doi.org/10.1158/1078-0432.31248962","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31248962","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7127648294","https://openalex.org/W4416866060","https://openalex.org/W3089216627","https://openalex.org/W4397007311","https://openalex.org/W3130455329","https://openalex.org/W4220697481","https://openalex.org/W4253279781","https://openalex.org/W3088678485","https://openalex.org/W3087853974","https://openalex.org/W6958567574"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"S4":[2],"|":[3],"Progression-free":[4],"survival":[5],"in":[6],"the":[7,11,25],"efficacy":[8],"cohort":[9],"since":[10],"initiation":[12],"of":[13],"first-line":[14,26],"treatment":[15,27],"for":[16,28],"advanced":[17],"disease":[18],"(N":[19],"=":[20],"16).":[21],"Kaplan-Meier":[22],"curve":[23],"from":[24],"metastatic":[29],"breast":[30],"cancer":[31],"with":[32],"trastuzumab":[33],"plus":[34,36],"pertuzumab":[35],"chemotherapy.":[37],"CI,":[38],"confidence":[39],"interval;":[40],"NR;":[41],"not":[42],"reported;":[43],"PFS,":[44],"progression-free":[45],"survival.":[46]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-02-06T00:00:00"}